CHSN
Chanson International Holding
There isn't enough reported data to score CHSN yet.
LCID
Lucid Group, Inc.
LCID lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
CHSN Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Strong | |
| Unavailable | |
| Strong |
CHSN's profitability and balance sheet are currently strong. There isn't enough data to rate its revenue and cash flow.
LCID Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
LCID's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
CHSN PE Valuation
CHSN has no meaningful PE right now: it lost money over the past year.
LCID PE Valuation
LCID has no meaningful PE right now: it lost money over the past year.
CHSN Forward outlook
There aren't enough analyst estimates for CHSN to show an outlook.
LCID Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect LCID's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
CHSN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2024 | $400.00 | +1567% |
CHSN and LCID do not have enough comparable growth data to identify a winner.
LCID Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$13.08 | -$2.57 |
| Q2 2026 | -$13.65 | -$2.35 |
| Q1 2026 | -$13.15 | -$1.25 |
| Q4 2025 | -$12.09 | +$0.41 |
| Q3 2025 | -$10.51 | +$2.49 |
| Q2 2025 | -$11.30 | +$0.40 |
| Q1 2025 | -$11.90 | +$0.40 |
| Q4 2024 | -$12.50 | +$1.10 |
LCID is still losing money, but less than at its worst: $13.08 per share over the past year, against $16.50 at its worst in mid-2023.
CHSN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $8.3M | -4.5% |
| Q4 2025 | $9.6M | -10% |
| Q2 2025 | $8.7M | +15% |
| Q4 2024 | $10.7M | +27% |
| Q2 2024 | $7.5M | -14% |
| Q4 2023 | $8.4M | +79% |
| Q2 2023 | $8.8M | +3.1% |
| Q4 2022 | $4.7M | -41% |
CHSN has the edge over LCID in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -9.4% | -2 points |
| Q4 2025 | -7.3% | +1.3 points |
| Q2 2025 | -14% | -15 points |
| Q4 2024 | 0.3% | +32 points |
| Q2 2024 | -7.4% | -6.9 points |
| Q4 2023 | -8.6% | -4.6 points |
| Q2 2023 | 1.3% | +5.3 points |
| Q4 2022 | -32% | -20 points |
CHSN has the edge over LCID on profitability, with a higher operating margin.
LCID Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $350.3M | +4.1% |
| Q2 2026 | $405.3M | +56% |
| Q1 2026 | $282.5M | +20% |
| Q4 2025 | $522.7M | +123% |
| Q3 2025 | $336.6M | +68% |
| Q2 2025 | $259.4M | +29% |
| Q1 2025 | $235M | +36% |
| Q4 2024 | $234.5M | +49% |
LCID's revenue has grown year over year for 11 quarters in a row: $350M last quarter, up 4.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -245% | +35 points |
| Q2 2026 | -267% | +43 points |
| Q1 2026 | -350% | -56 points |
| Q4 2025 | -204% | +109 points |
| Q3 2025 | -280% | +105 points |
| Q2 2025 | -310% | +83 points |
| Q1 2025 | -294% | +128 points |
| Q4 2024 | -313% | +156 points |
LCID's operating margin was −245% last quarter, up 35 points from the same quarter a year ago, near the top of its range since 2020.
CHSN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2024 | $2.2M | +$6.4M |
| Q2 2024 | $771.9K | +68% |
| Q4 2023 | -$4.2M | -778% |
| Q2 2023 | $458.1K | +$1.4M |
| Q4 2022 | $617.7K | +$1M |
| Q2 2022 | -$926.4K | -738% |
| Q4 2021 | -$405.1K | -164% |
| Q2 2021 | $145.3K | +263% |
CHSN's free cash flow was −$4M over the past year, against −$255,670 the year before.
LCID Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1B | -$84.2M |
| Q2 2026 | -$1.5B | -$463.2M |
| Q1 2026 | -$1.4B | -$849M |
| Q4 2025 | -$1.2B | -$417.1M |
| Q3 2025 | -$955.5M | -$333M |
| Q2 2025 | -$1B | -$271.6M |
| Q1 2025 | -$589.9M | +$125.1M |
| Q4 2024 | -$824.8M | -$77.6M |
LCID has burned cash in almost every quarter: −$5.2B over the past year, against −$3.4B the year before.
CHSN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +85094% | +1.3M shares |
| 1 year | +730% | +1.2M shares |
CHSN has 1M diluted shares, up 730% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q4 2022 | — |
| Q2 2022 | — |
| Q4 2021 | — |
| Q2 2021 | — |
| Q4 2020 | — |
| Q2 2020 | — |
| Q4 2019 | — |
LCID Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.3% | +12.5M shares |
| 1 year | +26% | +82.4M shares |
| 3 years | +73% | +166M shares |
LCID has the edge over CHSN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | $2.2M |
| Q1 2020 | — |
CHSN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2024 | -36.0x | Net Cash |
CHSN has more cash than debt.
LCID Net Leverage
LCID's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
CHSN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.6 | Neutral |
| Stochastic | 35.1 | Neutral |
CHSN's weekly RSI is 33 (neutral) and its Stochastic is 35 (neutral).
LCID Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.9 | Neutral |
| Stochastic | 7.1 | Oversold |
LCID's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
CHSN PE vs Consumer Cyclical Sector
| Metric | CHSN | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 18x | — |
CHSN has no meaningful PE right now: it lost money over the past year.
LCID PE vs Consumer Cyclical Sector
LCID has no meaningful PE right now: it lost money over the past year.
CHSN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.25 | 52% below |
| 20 week MA | $1.15 | 48% below |
| 50 week MA | $92.1 | 99% below |
| 100 week MA | $3,017.9 | 100% below |
LCID has stronger trend alignment. CHSN is above 0 of 4 weekly averages versus LCID above 0 of 5.
LCID Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.53 | 7.9% below |
| 20 week MA | $4.88 | 33% below |
| 50 week MA | $7.33 | 56% below |
| 100 week MA | $15.4 | 79% below |
| 200 week MA | $31.9 | 90% below |
LCID is in a downtrend: it's below all five of its weekly moving averages, and 90% below its 200-week average.
CHSN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2023 | $16,880.0 | $9,760.0 | -42% |
| 2024 | $9,760.0 | $46,320.0 | +375% |
| 2025 | $46,320.0 | $209.0 | -100% |
| 2026 YTD | $209.0 | $0.60 | -100% |
CHSN's yearly returns have swung widely, from +375% in 2024 to −100% in 2025. It's down 100% so far in 2026.
LCID Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $98.9 | $100.4 | +1.5% |
| 2021 | $100.4 | $376.4 | +275% |
| 2022 | $376.4 | $67.0 | -82% |
| 2023 | $67.0 | $42.1 | -37% |
| 2024 | $42.1 | $32.0 | -24% |
| 2025 | $32.0 | $11.4 | -64% |
| 2026 YTD | $11.4 | $3.25 | -72% |
LCID has the edge over CHSN on returns for 2026, with the stronger performance.